Enterin the gut

How Enterin’s compound could help treat Parkinson’s disease constipation

Enterin Inc. has a new twist on the longstanding Parkinson’s disease target alpha synuclein. The biotech is inhibiting the protein’s accumulation in intestinal nerves rather than in the brain, with the goal of treating constipation and non-motor symptoms associated with the disease.

Alpha synuclein (SNCA) is a major component of Lewy bodies, a type of protein aggregate that builds up in the brains of PD

Read the full 643 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE